Loading
2 treatment settings, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Surveillance and chemoprevention (tamoxifen or an aromatase inhibitor); TAM-01 tested low-dose tamoxifen in intraepithelial neoplasia.
The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.
Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.
Add these to your appointment list, or take the full question set for this cancer.
Excision to clear margins because of the upgrade rate to invasive cancer or ductal carcinoma in situ.
This setting names no product or technology record yet; the approach above is the standard as written. Ask your team which specific treatments they mean.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
Add these to your appointment list, or take the full question set for this cancer.